This report, miRNA Research and Diagnostic Markets, focuses on the test product potential of microRNA. These pieces of RNA are seen as important regulators of gene expression; including growth, form, differentiation, and apoptosis. They serve myriad functions as regulator molecules in post-transcriptional gene silencing.
As the study details, a wide range of companies, both small biotechs and big pharmaceutical companies are committed to miRNA diagnostics.
As part of its coverage of this topic, this report includes the following:
Discussion of miRNAs
Upside for miRNA Diagnostic Technologies
miRNAs and Neurological Disorders
Prostate Cancer Screening and miRNAs
miRNAs and Resistance to Anti-Cancer Drugs
Discussion of Patent Issues
Interviews with Industry Experts
miRNA and Metastatic Brain Lesions
As part of its coverage, the miRNA offerings and products in developments in the following companies are extensively reviewed:
Mello Biotechnology Inc.
Pacific Edge Biotechnology
Santaris Pharma A/S
Diagnostics: Small RNA Assays and Biomarker Validation
Tekmira Pharmaceuticals Corporation
Thermo Fisher Scientific, Inc.
Eisai Biomarkers and Personalized Medicine
Genomic Health Inc.
GlaxoSmithKline Discovery and Molecular Toxicology
Groove Biopharma (formerly Mirina)
Hologic-Gen Probe Inc
Search inside this report
Departmental Site License (one location, 10 users)